Stock Track | UroGen Pharma Soars 13.70% Intraday on Strong Q1 Earnings Beat and 152% Revenue Growth

Stock Track

May 07

UroGen Pharma Ltd.'s (URGN) stock price soared 13.70% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results.

The biopharmaceutical company reported quarterly sales of $50.959 million, which exceeded analyst consensus estimates by 13.70%. Revenue surged 152% year-over-year, driven primarily by the successful commercial launch and broader adoption of ZUSDURI, supported by a permanent J Code that improved reimbursement starting in January 2026. The company's net loss also narrowed significantly, with a reported loss per share of $0.47, beating the estimated loss of $0.48.

Additional positive drivers included a 7% year-over-year increase in JELMYTO revenue, the reiteration of full-year 2026 guidance, and the company's plan to submit a New Drug Application for UGN-103 in the second half of the year, contributing to the strong positive investor sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1162860097"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162860097\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162860097?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 02:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162860097","market":"nz","top_or_hot":-1,"title":"Stock Track | UroGen Pharma Soars 13.70% Intraday on Strong Q1 Earnings Beat and 152% Revenue Growth","media":"Stock Track","content":"<p>UroGen Pharma Ltd.'s (URGN) stock price soared 13.70% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results.</p><p>The biopharmaceutical company reported quarterly sales of $50.959 million, which exceeded analyst consensus estimates by 13.70%. Revenue surged 152% year-over-year, driven primarily by the successful commercial launch and broader adoption of ZUSDURI, supported by a permanent J Code that improved reimbursement starting in January 2026. The company's net loss also narrowed significantly, with a reported loss per share of $0.47, beating the estimated loss of $0.48.</p><p>Additional positive drivers included a 7% year-over-year increase in JELMYTO revenue, the reiteration of full-year 2026 guidance, and the company's plan to submit a New Drug Application for UGN-103 in the second half of the year, contributing to the strong positive investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | UroGen Pharma Soars 13.70% Intraday on Strong Q1 Earnings Beat and 152% Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | UroGen Pharma Soars 13.70% Intraday on Strong Q1 Earnings Beat and 152% Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 02:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UroGen Pharma Ltd.'s (URGN) stock price soared 13.70% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results.</p><p>The biopharmaceutical company reported quarterly sales of $50.959 million, which exceeded analyst consensus estimates by 13.70%. Revenue surged 152% year-over-year, driven primarily by the successful commercial launch and broader adoption of ZUSDURI, supported by a permanent J Code that improved reimbursement starting in January 2026. The company's net loss also narrowed significantly, with a reported loss per share of $0.47, beating the estimated loss of $0.48.</p><p>Additional positive drivers included a 7% year-over-year increase in JELMYTO revenue, the reiteration of full-year 2026 guidance, and the company's plan to submit a New Drug Application for UGN-103 in the second half of the year, contributing to the strong positive investor sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"URGN","symbol_name":"乌龙制药","start_time":0,"source_url":"","article_id":"1162860097","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162860097","pubTimestamp":1778091500,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"UroGen Pharma Ltd.'s (URGN) stock price soared 13.70% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results.The biopharmaceutical company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"URGN":"乌龙制药"},"translate_title":"个股追踪|UroGen Pharma盘中飙升13.70%，Q1盈利强劲，营收增长152%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"URGN":1},"content_text":"UroGen Pharma Ltd.'s (URGN) stock price soared 13.70% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results.The biopharmaceutical company reported quarterly sales of $50.959 million, which exceeded analyst consensus estimates by 13.70%. Revenue surged 152% year-over-year, driven primarily by the successful commercial launch and broader adoption of ZUSDURI, supported by a permanent J Code that improved reimbursement starting in January 2026. The company's net loss also narrowed significantly, with a reported loss per share of $0.47, beating the estimated loss of $0.48.Additional positive drivers included a 7% year-over-year increase in JELMYTO revenue, the reiteration of full-year 2026 guidance, and the company's plan to submit a New Drug Application for UGN-103 in the second half of the year, contributing to the strong positive investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}